APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Factor Xa Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Factor Xa Inhibitors Market Analysis and Forecast 2026-2032

Report ID 173990660229 December 2025214 pages

Choose your research edition.

Industry ResearchFactor Xa Inhibitors Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Factor Xa Inhibitors Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Factor Xa Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Factor Xa Inhibitors Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Factor Xa Inhibitors Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Factor Xa Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Factor Xa Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Factor Xa Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Factor Xa Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Factor Xa Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Factor Xa Inhibitors include Chia Tai Tianqing Pharmaceutical, Zhejiang Hisun Pharmaceutical, Cspc Ouyi Pharmaceutical, Qilu Pharmaceutical, Nanjing King-Friend Biochemical Pharmaceutical, Kelun Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Shanghai Huilun Pharmaceutical and Hansoh Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Factor Xa Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Factor Xa Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for Factor Xa Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Factor Xa Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Factor Xa Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Factor Xa Inhibitors sales, projected growth trends, production technology, application and end-user industry.

Factor Xa Inhibitors Segment by Company

Chia Tai Tianqing Pharmaceutical

Zhejiang Hisun Pharmaceutical

Cspc Ouyi Pharmaceutical

Qilu Pharmaceutical

Nanjing King-Friend Biochemical Pharmaceutical

Kelun Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Shanghai Huilun Pharmaceutical

Hansoh Pharma

HEC Pharma

BrightGene

Zydus

Viatris

Pfizer

Lupin

Janssen Pharmaceuticals

GlaxoSmithKline

Eugia Pharma

Dr. Reddy's Laboratories

Daiichi Sankyo

Bristol Myers Squibb

Bayer

Apotex

Accord Healthcare

Factor Xa Inhibitors Segment by Type

Oral Drugs

Injections

Factor Xa Inhibitors Segment by Application

Atrial Fibrillation

Deep Vein Thrombosis

Pulmonary Embolism

Other

Factor Xa Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Factor Xa Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Factor Xa Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Factor Xa Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Factor Xa Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Factor Xa Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Factor Xa Inhibitors sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Factor Xa Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Drugs Major Manufacturers Table 3. Injections Major Manufacturers Table 4. Global Factor Xa Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Atrial Fibrillation Major Manufacturers Table 6. Deep Vein Thrombosis Major Manufacturers Table 7. Pulmonary Embolism Major Manufacturers Table 8. Other Major Manufacturers Table 9. Factor Xa Inhibitors Industry Trends Table 10. Factor Xa Inhibitors Industry Drivers Table 11. Factor Xa Inhibitors Industry Opportunities and Challenges Table 12. Factor Xa Inhibitors Industry Restraints Table 13. Global Factor Xa Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Factor Xa Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Factor Xa Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Factor Xa Inhibitors Revenue Market Share by Region (2021-2026) Table 17. Global Factor Xa Inhibitors Revenue Market Share by Region (2027-2032) Table 18. Global Factor Xa Inhibitors Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Factor Xa Inhibitors Sales by Region (2021-2026) & (K Units) Table 20. Global Factor Xa Inhibitors Sales by Region (2027-2032) & (K Units) Table 21. Global Factor Xa Inhibitors Sales Market Share by Region (2021-2026) Table 22. Global Factor Xa Inhibitors Sales Market Share by Region (2027-2032) Table 23. Global Factor Xa Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Factor Xa Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Factor Xa Inhibitors Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Factor Xa Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 27. Global Factor Xa Inhibitors Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Factor Xa Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Factor Xa Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Factor Xa Inhibitors Manufacturers, Product Type & Application Table 31. Global Factor Xa Inhibitors Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Factor Xa Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Factor Xa Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Factor Xa Inhibitors Revenue Market Share by Type (2021-2026) Table 38. Global Factor Xa Inhibitors Revenue Market Share by Type (2027-2032) Table 39. Global Factor Xa Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 41. Global Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 42. Global Factor Xa Inhibitors Sales Market Share by Type (2021-2026) Table 43. Global Factor Xa Inhibitors Sales Market Share by Type (2027-2032) Table 44. Global Factor Xa Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 45. Global Factor Xa Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 46. Global Factor Xa Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Factor Xa Inhibitors Revenue Market Share by Application (2021-2026) Table 50. Global Factor Xa Inhibitors Revenue Market Share by Application (2027-2032) Table 51. Global Factor Xa Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 53. Global Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 54. Global Factor Xa Inhibitors Sales Market Share by Application (2021-2026) Table 55. Global Factor Xa Inhibitors Sales Market Share by Application (2027-2032) Table 56. Global Factor Xa Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 57. Global Factor Xa Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 58. Chia Tai Tianqing Pharmaceutical Company Information Table 59. Chia Tai Tianqing Pharmaceutical Business Overview Table 60. Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 62. Chia Tai Tianqing Pharmaceutical Recent Development Table 63. Zhejiang Hisun Pharmaceutical Company Information Table 64. Zhejiang Hisun Pharmaceutical Business Overview Table 65. Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 67. Zhejiang Hisun Pharmaceutical Recent Development Table 68. Cspc Ouyi Pharmaceutical Company Information Table 69. Cspc Ouyi Pharmaceutical Business Overview Table 70. Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 72. Cspc Ouyi Pharmaceutical Recent Development Table 73. Qilu Pharmaceutical Company Information Table 74. Qilu Pharmaceutical Business Overview Table 75. Qilu Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Qilu Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 77. Qilu Pharmaceutical Recent Development Table 78. Nanjing King-Friend Biochemical Pharmaceutical Company Information Table 79. Nanjing King-Friend Biochemical Pharmaceutical Business Overview Table 80. Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 82. Nanjing King-Friend Biochemical Pharmaceutical Recent Development Table 83. Kelun Pharmaceutical Company Information Table 84. Kelun Pharmaceutical Business Overview Table 85. Kelun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Kelun Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 87. Kelun Pharmaceutical Recent Development Table 88. Jiangsu Hengrui Pharmaceuticals Company Information Table 89. Jiangsu Hengrui Pharmaceuticals Business Overview Table 90. Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Product Portfolio Table 92. Jiangsu Hengrui Pharmaceuticals Recent Development Table 93. Shanghai Huilun Pharmaceutical Company Information Table 94. Shanghai Huilun Pharmaceutical Business Overview Table 95. Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 97. Shanghai Huilun Pharmaceutical Recent Development Table 98. Hansoh Pharma Company Information Table 99. Hansoh Pharma Business Overview Table 100. Hansoh Pharma Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Hansoh Pharma Factor Xa Inhibitors Product Portfolio Table 102. Hansoh Pharma Recent Development Table 103. HEC Pharma Company Information Table 104. HEC Pharma Business Overview Table 105. HEC Pharma Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. HEC Pharma Factor Xa Inhibitors Product Portfolio Table 107. HEC Pharma Recent Development Table 108. BrightGene Company Information Table 109. BrightGene Business Overview Table 110. BrightGene Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. BrightGene Factor Xa Inhibitors Product Portfolio Table 112. BrightGene Recent Development Table 113. Zydus Company Information Table 114. Zydus Business Overview Table 115. Zydus Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Zydus Factor Xa Inhibitors Product Portfolio Table 117. Zydus Recent Development Table 118. Viatris Company Information Table 119. Viatris Business Overview Table 120. Viatris Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Viatris Factor Xa Inhibitors Product Portfolio Table 122. Viatris Recent Development Table 123. Pfizer Company Information Table 124. Pfizer Business Overview Table 125. Pfizer Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Pfizer Factor Xa Inhibitors Product Portfolio Table 127. Pfizer Recent Development Table 128. Lupin Company Information Table 129. Lupin Business Overview Table 130. Lupin Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Lupin Factor Xa Inhibitors Product Portfolio Table 132. Lupin Recent Development Table 133. Janssen Pharmaceuticals Company Information Table 134. Janssen Pharmaceuticals Business Overview Table 135. Janssen Pharmaceuticals Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Janssen Pharmaceuticals Factor Xa Inhibitors Product Portfolio Table 137. Janssen Pharmaceuticals Recent Development Table 138. GlaxoSmithKline Company Information Table 139. GlaxoSmithKline Business Overview Table 140. GlaxoSmithKline Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. GlaxoSmithKline Factor Xa Inhibitors Product Portfolio Table 142. GlaxoSmithKline Recent Development Table 143. Eugia Pharma Company Information Table 144. Eugia Pharma Business Overview Table 145. Eugia Pharma Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Eugia Pharma Factor Xa Inhibitors Product Portfolio Table 147. Eugia Pharma Recent Development Table 148. Dr. Reddy's Laboratories Company Information Table 149. Dr. Reddy's Laboratories Business Overview Table 150. Dr. Reddy's Laboratories Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Dr. Reddy's Laboratories Factor Xa Inhibitors Product Portfolio Table 152. Dr. Reddy's Laboratories Recent Development Table 153. Daiichi Sankyo Company Information Table 154. Daiichi Sankyo Business Overview Table 155. Daiichi Sankyo Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Daiichi Sankyo Factor Xa Inhibitors Product Portfolio Table 157. Daiichi Sankyo Recent Development Table 158. Bristol Myers Squibb Company Information Table 159. Bristol Myers Squibb Business Overview Table 160. Bristol Myers Squibb Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Bristol Myers Squibb Factor Xa Inhibitors Product Portfolio Table 162. Bristol Myers Squibb Recent Development Table 163. Bayer Company Information Table 164. Bayer Business Overview Table 165. Bayer Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Bayer Factor Xa Inhibitors Product Portfolio Table 167. Bayer Recent Development Table 168. Apotex Company Information Table 169. Apotex Business Overview Table 170. Apotex Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 171. Apotex Factor Xa Inhibitors Product Portfolio Table 172. Apotex Recent Development Table 173. Accord Healthcare Company Information Table 174. Accord Healthcare Business Overview Table 175. Accord Healthcare Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 176. Accord Healthcare Factor Xa Inhibitors Product Portfolio Table 177. Accord Healthcare Recent Development Table 178. North America Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 179. North America Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 180. North America Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 181. North America Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 182. North America Factor Xa Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 183. North America Factor Xa Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 184. North America Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 185. North America Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 186. North America Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 187. North America Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 188. North America Factor Xa Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 189. North America Factor Xa Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 190. North America Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 191. North America Factor Xa Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 192. North America Factor Xa Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 193. North America Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 194. North America Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 195. North America Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 196. North America Factor Xa Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 197. North America Factor Xa Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 198. United States Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 199. Canada Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 200. Mexico Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 201. Europe Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 202. Europe Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 203. Europe Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 204. Europe Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 205. Europe Factor Xa Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 206. Europe Factor Xa Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 207. Europe Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 208. Europe Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 209. Europe Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 210. Europe Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 211. Europe Factor Xa Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 212. Europe Factor Xa Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 213. Europe Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 214. Europe Factor Xa Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 215. Europe Factor Xa Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 216. Europe Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 217. Europe Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 218. Europe Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 219. Europe Factor Xa Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 220. Europe Factor Xa Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 221. Germany Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 222. France Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 223. U.K. Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 224. Italy Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 225. Russia Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 226. Spain Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 227. Netherlands Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 228. Switzerland Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 229. Sweden Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 230. Poland Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 231. China Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 232. China Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 233. China Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 234. China Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 235. China Factor Xa Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 236. China Factor Xa Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 237. China Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 238. China Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 239. China Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 240. China Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 241. China Factor Xa Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 242. China Factor Xa Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 243. Asia Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 244. Asia Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 245. Asia Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 246. Asia Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 247. Asia Factor Xa Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 248. Asia Factor Xa Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 249. Asia Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 250. Asia Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 251. Asia Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 252. Asia Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 253. Asia Factor Xa Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 254. Asia Factor Xa Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 255. Asia Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 256. Asia Factor Xa Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 257. Asia Factor Xa Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 258. Asia Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 259. Asia Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 260. Asia Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 261. Asia Factor Xa Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 262. Asia Factor Xa Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 263. Japan Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 264. South Korea Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 265. India Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 266. Australia Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 267. Taiwan Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 268. Southeast Asia Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 269. SAMEA Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 270. SAMEA Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 271. SAMEA Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 272. SAMEA Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 273. SAMEA Factor Xa Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 274. SAMEA Factor Xa Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 275. SAMEA Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 276. SAMEA Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 277. SAMEA Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 278. SAMEA Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 279. SAMEA Factor Xa Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 280. SAMEA Factor Xa Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 281. SAMEA Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 282. SAMEA Factor Xa Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 283. SAMEA Factor Xa Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 284. SAMEA Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 285. SAMEA Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 286. SAMEA Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 287. SAMEA Factor Xa Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 288. SAMEA Factor Xa Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 289. Brazil Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 290. Argentina Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 291. Chile Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 292. Colombia Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 293. Peru Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 294. Saudi Arabia Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 295. Israel Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 296. UAE Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 297. Turkey Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 298. Iran Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 299. Egypt Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 300. Key Raw Materials Table 301. Raw Materials Key Suppliers Table 302. Factor Xa Inhibitors Distributors List Table 303. Factor Xa Inhibitors Customers List Table 304. Research Programs/Design for This Report Table 305. Authors List of This Report Table 306. Secondary Sources Table 307. Primary Sources List of Figures Figure 1. Factor Xa Inhibitors Image Figure 2. Global Factor Xa Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Factor Xa Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Drugs Image Figure 5. Injections Image Figure 6. Global Factor Xa Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Factor Xa Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 8. Atrial Fibrillation Image Figure 9. Deep Vein Thrombosis Image Figure 10. Pulmonary Embolism Image Figure 11. Other Image Figure 12. Global Factor Xa Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Figure 14. Global Factor Xa Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Factor Xa Inhibitors Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Factor Xa Inhibitors Revenue Market Share by Region (2021-2032) Figure 17. Global Factor Xa Inhibitors Sales (2021-2032) & (K Units) Figure 18. Global Factor Xa Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Factor Xa Inhibitors Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Factor Xa Inhibitors Sales YoY (2021-2032) & (K Units) Figure 21. Europe Factor Xa Inhibitors Sales YoY (2021-2032) & (K Units) Figure 22. China Factor Xa Inhibitors Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Factor Xa Inhibitors Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Factor Xa Inhibitors Sales YoY (2021-2032) & (K Units) Figure 25. Global Factor Xa Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Factor Xa Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Factor Xa Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Factor Xa Inhibitors Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Factor Xa Inhibitors Revenue Market Share by Type (2021-2032) Figure 31. Global Factor Xa Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Factor Xa Inhibitors Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Factor Xa Inhibitors Sales Market Share by Type (2021-2032) Figure 34. Global Factor Xa Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Factor Xa Inhibitors Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Factor Xa Inhibitors Revenue Market Share by Application (2021-2032) Figure 37. Global Factor Xa Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global Factor Xa Inhibitors Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Factor Xa Inhibitors Sales Market Share by Application (2021-2032) Figure 40. North America Factor Xa Inhibitors Revenue Share by Type (2021-2032) Figure 41. North America Factor Xa Inhibitors Sales Share by Type (2021-2032) Figure 42. North America Factor Xa Inhibitors Revenue Share by Application (2021-2032) Figure 43. North America Factor Xa Inhibitors Sales Share by Application (2021-2032) Figure 44. North America Factor Xa Inhibitors Revenue Share by Country (2021-2032) Figure 45. North America Factor Xa Inhibitors Sales Share by Country (2021-2032) Figure 46. Europe Factor Xa Inhibitors Revenue Share by Type (2021-2032) Figure 47. Europe Factor Xa Inhibitors Sales Share by Type (2021-2032) Figure 48. Europe Factor Xa Inhibitors Revenue Share by Application (2021-2032) Figure 49. Europe Factor Xa Inhibitors Sales Share by Application (2021-2032) Figure 50. Europe Factor Xa Inhibitors Revenue Share by Country (2021-2032) Figure 51. Europe Factor Xa Inhibitors Sales Share by Country (2021-2032) Figure 52. China Factor Xa Inhibitors Revenue Share by Type (2021-2032) Figure 53. China Factor Xa Inhibitors Sales Share by Type (2021-2032) Figure 54. China Factor Xa Inhibitors Revenue Share by Application (2021-2032) Figure 55. China Factor Xa Inhibitors Sales Share by Application (2021-2032) Figure 56. Asia Factor Xa Inhibitors Revenue Share by Type (2021-2032) Figure 57. Asia Factor Xa Inhibitors Sales Share by Type (2021-2032) Figure 58. Asia Factor Xa Inhibitors Revenue Share by Application (2021-2032) Figure 59. Asia Factor Xa Inhibitors Sales Share by Application (2021-2032) Figure 60. Asia Factor Xa Inhibitors Revenue Share by Country (2021-2032) Figure 61. Asia Factor Xa Inhibitors Sales Share by Country (2021-2032) Figure 62. SAMEA Factor Xa Inhibitors Revenue Share by Type (2021-2032) Figure 63. SAMEA Factor Xa Inhibitors Sales Share by Type (2021-2032) Figure 64. SAMEA Factor Xa Inhibitors Revenue Share by Application (2021-2032) Figure 65. SAMEA Factor Xa Inhibitors Sales Share by Application (2021-2032) Figure 66. SAMEA Factor Xa Inhibitors Revenue Share by Country (2021-2032) Figure 67. SAMEA Factor Xa Inhibitors Sales Share by Country (2021-2032) Figure 68. Factor Xa Inhibitors Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Factor Xa Inhibitors Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Drugs
  • Injections
Applications
  • Atrial Fibrillation
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Cspc Ouyi Pharmaceutical
  • Qilu Pharmaceutical
  • Nanjing King-Friend Biochemical Pharmaceutical
  • Kelun Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Shanghai Huilun Pharmaceutical
  • Hansoh Pharma
  • HEC Pharma
  • BrightGene
  • Zydus
  • Viatris
  • Pfizer
  • Lupin
  • Janssen Pharmaceuticals
  • GlaxoSmithKline
  • Eugia Pharma
  • Dr. Reddy's Laboratories
  • Daiichi Sankyo
  • Bristol Myers Squibb
  • Bayer
  • Apotex
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Factor Xa Inhibitors Market by Type
  3. 1.2.1 Global Factor Xa Inhibitors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral Drugs
  5. 1.2.3 Injections
  6. 1.3 Factor Xa Inhibitors Market by Application
  7. 1.3.1 Global Factor Xa Inhibitors Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Atrial Fibrillation
  9. 1.3.3 Deep Vein Thrombosis
  10. 1.3.4 Pulmonary Embolism
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Factor Xa Inhibitors Market Dynamics
  1. 2.1 Factor Xa Inhibitors Industry Trends
  2. 2.2 Factor Xa Inhibitors Industry Drivers
  3. 2.3 Factor Xa Inhibitors Industry Opportunities and Challenges
  4. 2.4 Factor Xa Inhibitors Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Factor Xa Inhibitors Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Factor Xa Inhibitors Revenue by Region
  3. 3.2.1 Global Factor Xa Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Factor Xa Inhibitors Revenue by Region (2021-2026)
  5. 3.2.3 Global Factor Xa Inhibitors Revenue by Region (2027-2032)
  6. 3.2.4 Global Factor Xa Inhibitors Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Factor Xa Inhibitors Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Factor Xa Inhibitors Sales by Region
  9. 3.4.1 Global Factor Xa Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Factor Xa Inhibitors Sales by Region (2021-2026)
  11. 3.4.3 Global Factor Xa Inhibitors Sales by Region (2027-2032)
  12. 3.4.4 Global Factor Xa Inhibitors Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Factor Xa Inhibitors Revenue by Manufacturers
  2. 4.1.1 Global Factor Xa Inhibitors Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Factor Xa Inhibitors Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Factor Xa Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Factor Xa Inhibitors Sales by Manufacturers
  6. 4.2.1 Global Factor Xa Inhibitors Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Factor Xa Inhibitors Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Factor Xa Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Factor Xa Inhibitors Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Factor Xa Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Factor Xa Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Factor Xa Inhibitors Manufacturers, Product Type & Application
  13. 4.7 Global Factor Xa Inhibitors Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Factor Xa Inhibitors Market CR5 and HHI
  16. 4.8.2 2025 Factor Xa Inhibitors Tier 1, Tier 2, and Tier 3
5 Factor Xa Inhibitors Market by Type
  1. 5.1 Global Factor Xa Inhibitors Revenue by Type
  2. 5.1.1 Global Factor Xa Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Factor Xa Inhibitors Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Factor Xa Inhibitors Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Factor Xa Inhibitors Sales by Type
  6. 5.2.1 Global Factor Xa Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Factor Xa Inhibitors Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Factor Xa Inhibitors Sales Market Share by Type (2021-2032)
  9. 5.3 Global Factor Xa Inhibitors Price by Type
6 Factor Xa Inhibitors Market by Application
  1. 6.1 Global Factor Xa Inhibitors Revenue by Application
  2. 6.1.1 Global Factor Xa Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Factor Xa Inhibitors Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Factor Xa Inhibitors Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Factor Xa Inhibitors Sales by Application
  6. 6.2.1 Global Factor Xa Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Factor Xa Inhibitors Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Factor Xa Inhibitors Sales Market Share by Application (2021-2032)
  9. 6.3 Global Factor Xa Inhibitors Price by Application
7 Company Profiles
  1. 7.1 Chia Tai Tianqing Pharmaceutical
  2. 7.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 7.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 7.1.3 Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Product Portfolio
  6. 7.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 7.2 Zhejiang Hisun Pharmaceutical
  8. 7.2.1 Zhejiang Hisun Pharmaceutical Company Information
  9. 7.2.2 Zhejiang Hisun Pharmaceutical Business Overview
  10. 7.2.3 Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Product Portfolio
  12. 7.2.5 Zhejiang Hisun Pharmaceutical Recent Developments
  13. 7.3 Cspc Ouyi Pharmaceutical
  14. 7.3.1 Cspc Ouyi Pharmaceutical Company Information
  15. 7.3.2 Cspc Ouyi Pharmaceutical Business Overview
  16. 7.3.3 Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Product Portfolio
  18. 7.3.5 Cspc Ouyi Pharmaceutical Recent Developments
  19. 7.4 Qilu Pharmaceutical
  20. 7.4.1 Qilu Pharmaceutical Company Information
  21. 7.4.2 Qilu Pharmaceutical Business Overview
  22. 7.4.3 Qilu Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Qilu Pharmaceutical Factor Xa Inhibitors Product Portfolio
  24. 7.4.5 Qilu Pharmaceutical Recent Developments
  25. 7.5 Nanjing King-Friend Biochemical Pharmaceutical
  26. 7.5.1 Nanjing King-Friend Biochemical Pharmaceutical Company Information
  27. 7.5.2 Nanjing King-Friend Biochemical Pharmaceutical Business Overview
  28. 7.5.3 Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Product Portfolio
  30. 7.5.5 Nanjing King-Friend Biochemical Pharmaceutical Recent Developments
  31. 7.6 Kelun Pharmaceutical
  32. 7.6.1 Kelun Pharmaceutical Company Information
  33. 7.6.2 Kelun Pharmaceutical Business Overview
  34. 7.6.3 Kelun Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Kelun Pharmaceutical Factor Xa Inhibitors Product Portfolio
  36. 7.6.5 Kelun Pharmaceutical Recent Developments
  37. 7.7 Jiangsu Hengrui Pharmaceuticals
  38. 7.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
  39. 7.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  40. 7.7.3 Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Product Portfolio
  42. 7.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  43. 7.8 Shanghai Huilun Pharmaceutical
  44. 7.8.1 Shanghai Huilun Pharmaceutical Company Information
  45. 7.8.2 Shanghai Huilun Pharmaceutical Business Overview
  46. 7.8.3 Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Product Portfolio
  48. 7.8.5 Shanghai Huilun Pharmaceutical Recent Developments
  49. 7.9 Hansoh Pharma
  50. 7.9.1 Hansoh Pharma Company Information
  51. 7.9.2 Hansoh Pharma Business Overview
  52. 7.9.3 Hansoh Pharma Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Hansoh Pharma Factor Xa Inhibitors Product Portfolio
  54. 7.9.5 Hansoh Pharma Recent Developments
  55. 7.10 HEC Pharma
  56. 7.10.1 HEC Pharma Company Information
  57. 7.10.2 HEC Pharma Business Overview
  58. 7.10.3 HEC Pharma Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 HEC Pharma Factor Xa Inhibitors Product Portfolio
  60. 7.10.5 HEC Pharma Recent Developments
  61. 7.11 BrightGene
  62. 7.11.1 BrightGene Company Information
  63. 7.11.2 BrightGene Business Overview
  64. 7.11.3 BrightGene Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 BrightGene Factor Xa Inhibitors Product Portfolio
  66. 7.11.5 BrightGene Recent Developments
  67. 7.12 Zydus
  68. 7.12.1 Zydus Company Information
  69. 7.12.2 Zydus Business Overview
  70. 7.12.3 Zydus Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Zydus Factor Xa Inhibitors Product Portfolio
  72. 7.12.5 Zydus Recent Developments
  73. 7.13 Viatris
  74. 7.13.1 Viatris Company Information
  75. 7.13.2 Viatris Business Overview
  76. 7.13.3 Viatris Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Viatris Factor Xa Inhibitors Product Portfolio
  78. 7.13.5 Viatris Recent Developments
  79. 7.14 Pfizer
  80. 7.14.1 Pfizer Company Information
  81. 7.14.2 Pfizer Business Overview
  82. 7.14.3 Pfizer Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Pfizer Factor Xa Inhibitors Product Portfolio
  84. 7.14.5 Pfizer Recent Developments
  85. 7.15 Lupin
  86. 7.15.1 Lupin Company Information
  87. 7.15.2 Lupin Business Overview
  88. 7.15.3 Lupin Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Lupin Factor Xa Inhibitors Product Portfolio
  90. 7.15.5 Lupin Recent Developments
  91. 7.16 Janssen Pharmaceuticals
  92. 7.16.1 Janssen Pharmaceuticals Company Information
  93. 7.16.2 Janssen Pharmaceuticals Business Overview
  94. 7.16.3 Janssen Pharmaceuticals Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Janssen Pharmaceuticals Factor Xa Inhibitors Product Portfolio
  96. 7.16.5 Janssen Pharmaceuticals Recent Developments
  97. 7.17 GlaxoSmithKline
  98. 7.17.1 GlaxoSmithKline Company Information
  99. 7.17.2 GlaxoSmithKline Business Overview
  100. 7.17.3 GlaxoSmithKline Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 GlaxoSmithKline Factor Xa Inhibitors Product Portfolio
  102. 7.17.5 GlaxoSmithKline Recent Developments
  103. 7.18 Eugia Pharma
  104. 7.18.1 Eugia Pharma Company Information
  105. 7.18.2 Eugia Pharma Business Overview
  106. 7.18.3 Eugia Pharma Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Eugia Pharma Factor Xa Inhibitors Product Portfolio
  108. 7.18.5 Eugia Pharma Recent Developments
  109. 7.19 Dr. Reddy's Laboratories
  110. 7.19.1 Dr. Reddy's Laboratories Company Information
  111. 7.19.2 Dr. Reddy's Laboratories Business Overview
  112. 7.19.3 Dr. Reddy's Laboratories Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Dr. Reddy's Laboratories Factor Xa Inhibitors Product Portfolio
  114. 7.19.5 Dr. Reddy's Laboratories Recent Developments
  115. 7.20 Daiichi Sankyo
  116. 7.20.1 Daiichi Sankyo Company Information
  117. 7.20.2 Daiichi Sankyo Business Overview
  118. 7.20.3 Daiichi Sankyo Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Daiichi Sankyo Factor Xa Inhibitors Product Portfolio
  120. 7.20.5 Daiichi Sankyo Recent Developments
  121. 7.21 Bristol Myers Squibb
  122. 7.21.1 Bristol Myers Squibb Company Information
  123. 7.21.2 Bristol Myers Squibb Business Overview
  124. 7.21.3 Bristol Myers Squibb Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Bristol Myers Squibb Factor Xa Inhibitors Product Portfolio
  126. 7.21.5 Bristol Myers Squibb Recent Developments
  127. 7.22 Bayer
  128. 7.22.1 Bayer Company Information
  129. 7.22.2 Bayer Business Overview
  130. 7.22.3 Bayer Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Bayer Factor Xa Inhibitors Product Portfolio
  132. 7.22.5 Bayer Recent Developments
  133. 7.23 Apotex
  134. 7.23.1 Apotex Company Information
  135. 7.23.2 Apotex Business Overview
  136. 7.23.3 Apotex Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Apotex Factor Xa Inhibitors Product Portfolio
  138. 7.23.5 Apotex Recent Developments
  139. 7.24 Accord Healthcare
  140. 7.24.1 Accord Healthcare Company Information
  141. 7.24.2 Accord Healthcare Business Overview
  142. 7.24.3 Accord Healthcare Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Accord Healthcare Factor Xa Inhibitors Product Portfolio
  144. 7.24.5 Accord Healthcare Recent Developments
8 North America
  1. 8.1 North America Factor Xa Inhibitors Market Size by Type
  2. 8.1.1 North America Factor Xa Inhibitors Revenue by Type (2021-2032)
  3. 8.1.2 North America Factor Xa Inhibitors Sales by Type (2021-2032)
  4. 8.1.3 North America Factor Xa Inhibitors Price by Type (2021-2032)
  5. 8.2 North America Factor Xa Inhibitors Market Size by Application
  6. 8.2.1 North America Factor Xa Inhibitors Revenue by Application (2021-2032)
  7. 8.2.2 North America Factor Xa Inhibitors Sales by Application (2021-2032)
  8. 8.2.3 North America Factor Xa Inhibitors Price by Application (2021-2032)
  9. 8.3 North America Factor Xa Inhibitors Market Size by Country
  10. 8.3.1 North America Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Factor Xa Inhibitors Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Factor Xa Inhibitors Market Size by Type
  2. 9.1.1 Europe Factor Xa Inhibitors Revenue by Type (2021-2032)
  3. 9.1.2 Europe Factor Xa Inhibitors Sales by Type (2021-2032)
  4. 9.1.3 Europe Factor Xa Inhibitors Price by Type (2021-2032)
  5. 9.2 Europe Factor Xa Inhibitors Market Size by Application
  6. 9.2.1 Europe Factor Xa Inhibitors Revenue by Application (2021-2032)
  7. 9.2.2 Europe Factor Xa Inhibitors Sales by Application (2021-2032)
  8. 9.2.3 Europe Factor Xa Inhibitors Price by Application (2021-2032)
  9. 9.3 Europe Factor Xa Inhibitors Market Size by Country
  10. 9.3.1 Europe Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Factor Xa Inhibitors Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Factor Xa Inhibitors Market Size by Type
  2. 10.1.1 China Factor Xa Inhibitors Revenue by Type (2021-2032)
  3. 10.1.2 China Factor Xa Inhibitors Sales by Type (2021-2032)
  4. 10.1.3 China Factor Xa Inhibitors Price by Type (2021-2032)
  5. 10.2 China Factor Xa Inhibitors Market Size by Application
  6. 10.2.1 China Factor Xa Inhibitors Revenue by Application (2021-2032)
  7. 10.2.2 China Factor Xa Inhibitors Sales by Application (2021-2032)
  8. 10.2.3 China Factor Xa Inhibitors Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Factor Xa Inhibitors Market Size by Type
  2. 11.1.1 Asia Factor Xa Inhibitors Revenue by Type (2021-2032)
  3. 11.1.2 Asia Factor Xa Inhibitors Sales by Type (2021-2032)
  4. 11.1.3 Asia Factor Xa Inhibitors Price by Type (2021-2032)
  5. 11.2 Asia Factor Xa Inhibitors Market Size by Application
  6. 11.2.1 Asia Factor Xa Inhibitors Revenue by Application (2021-2032)
  7. 11.2.2 Asia Factor Xa Inhibitors Sales by Application (2021-2032)
  8. 11.2.3 Asia Factor Xa Inhibitors Price by Application (2021-2032)
  9. 11.3 Asia Factor Xa Inhibitors Market Size by Country
  10. 11.3.1 Asia Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Factor Xa Inhibitors Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Factor Xa Inhibitors Market Size by Type
  2. 12.1.1 SAMEA Factor Xa Inhibitors Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Factor Xa Inhibitors Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Factor Xa Inhibitors Price by Type (2021-2032)
  5. 12.2 SAMEA Factor Xa Inhibitors Market Size by Application
  6. 12.2.1 SAMEA Factor Xa Inhibitors Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Factor Xa Inhibitors Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Factor Xa Inhibitors Price by Application (2021-2032)
  9. 12.3 SAMEA Factor Xa Inhibitors Market Size by Country
  10. 12.3.1 SAMEA Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Factor Xa Inhibitors Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Factor Xa Inhibitors Value Chain Analysis
  2. 13.1.1 Factor Xa Inhibitors Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Factor Xa Inhibitors Production Mode & Process
  6. 13.2 Factor Xa Inhibitors Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Factor Xa Inhibitors Distributors
  9. 13.2.3 Factor Xa Inhibitors Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst